Drug intelligence / Profile preview

SPR1

Development stage: Preclinical
Lead developer: Sporos BioDiscovery
Modality: Small Molecules

Overview

SPR1 is a drug developed by Sporos BioDiscovery, Inc., and is currently in the preclinical phase. It acts as a TEAD inhibitor, targeting TEA domain transcription factors. The primary indication for SPR1 is neoplasms.

Targets

TEAD (TEAD family)

Beyond the preview

Go deeper on SPR1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SPR1.

Explore the full profile